Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
- 1 December 2009
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (12) , 3173-3180
Abstract
In the past few years, the pro-apoptotic molecule Bim has attracted increasing attention as a plausible target for tumor therapy. A variety of normal and pathological systems regulated by Bim, dependent on cell type, apoptotic stimulation, and chemotherapeutic agents, have been documented. Bim promotes anoikis of many tumor cells, such as lung cancer, breast cancer, osteosarcoma, and melanoma. Various chemotherapeutic agents use Bim as a mediating executioner of cell death. Hence, Bim suppression supports metastasis and chemoresistance. Imatinib, gefitinib, bortezomib, and Bim protein itself are spotlighted as current and future Bim-targeting therapeutic agents. The potential benefits of Bim-targeted therapies are selectivity of treatment for tumor cells and reduction in tumor-associated phenomena such as chemoresistance and metastasis. Thus, Bim-targeting therapies may provide more effective and unique tumor management modalities in future. This review article discusses all these issues. [Mol Cancer Ther 2009;8(12):3173–80]Keywords
This publication has 50 references indexed in Scilit:
- TGFβ‐mediated BIM expression and apoptosis are regulated through SMAD3‐dependent expression of the MAPK phosphatase MKP2EMBO Reports, 2008
- RACK1 and CIS Mediate the Degradation of BimEL in Cancer CellsJournal of Biological Chemistry, 2008
- Multisite Phosphorylation Regulates Bim Stability and Apoptotic ActivityMolecular Cell, 2008
- Down-regulation of 14-3-3ζ suppresses anchorage-independent growth of lung cancer cells through anoikis activationProceedings of the National Academy of Sciences, 2008
- The BCL-2 protein family: opposing activities that mediate cell deathNature Reviews Molecular Cell Biology, 2008
- BH3 mimetics to improve cancer therapy; mechanisms and examplesDrug Resistance Updates, 2007
- c-Cbl is not required for ERK1/2-dependent degradation of BimELCellular Signalling, 2007
- The Bcl-2 apoptotic switch in cancer development and therapyOncogene, 2007
- BIM Regulates Apoptosis during Mammary Ductal Morphogenesis, and Its Absence Reveals Alternative Cell Death MechanismsDevelopmental Cell, 2007
- Bim and Bad mediate imatinib-induced killing of Bcr/Abl + leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticProceedings of the National Academy of Sciences, 2006